Recent News
Two Potential Mesothelioma Treatments Have No Positive Effect
Tremelimumab Earlier in the spring of 2017, scientists and researchers from the University of Salford in the UK published a special report questioning the effectiveness of the new immunotherapy treatment[…]
Improvements in Radiation Therapies Give More Treatment Options
When it comes to different treatments for mesothelioma patients, there is no shortage of diversity, as options include chemotherapy, radiation, surgery, immune-based therapies, gene-based therapies, and more. Chemotherapy treatments cisplatin[…]
Multiple Genetic Variants Increase Mesothelioma Risk
The term “high-risk predisposition,” is a well-known term in the cancer world that means a person could have certain genetic factors or other factors that places him or her at[…]
Mesothelioma Patients Receive Zoledronic Acid as Treatment
Known as a bisphosphonate, zoledronic acid is typically used for bone diseases such as osteoporosis, and to treat high calcium levels in the blood that can lead to other health[…]
Time Increases Risk for Mesothelioma, Study Finds
Asbestos-related illnesses such as mesothelioma and asbestosis have been known to develop over a period of decades, affecting people years and years since their last exposure. Many studies over the[…]
Giving Cediranib Another Chance
A Phase I study for cediranib, a VEGFR/PDGFR kinase inhibitor, showed promising results in shrinking tumor size and increasing survival rates for those suffering from malignant pleural mesothelioma. This is[…]
Calretinin More Effective Than Mesothelin in Detecting Mesothelioma Early
Mesothelioma is a rare and aggressive cancer that is difficult to diagnose because symptoms often mimic other diseases such as pulmonary fibrosis or lung cancer. Pathology reports and biopsies help[…]
Survival Rates Based Upon Subtypes of Mesothelioma
A recent study published in the British Journal of Cancer compared survival rates of mesothelioma patients that received their diagnosis through either cytological or by histological method for those with[…]
Phase I Clinical Trial Underway for CAR T-cell Therapy
A Phase I clinical trial for an immunotherapy treatment for malignant pleural mesothelioma and non-small cell lung cancer (NSCLC) is currently underway at the University of Pennsylvania in Philadelphia. Immunotherapy[…]
Pembrolizumab Update: Aduro Biotech Collaborates with Merck
A biopharmaceutical company named Aduro Biotech recently announced its collaboration with Merck to further evaluate the findings for the Phase II trial of KEYTRUDA ® (pembrolizumab) and to combine their[…]
Skip to content